Compare Adaptive Biotechnologies Corp (ADPT) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Plby Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Plby Group Inc trades at $1.33 (market cap $162.94M). The key difference: Adaptive Biotechnologies Corp is far larger — about 24.8× Plby Group Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | PLBY | |
|---|---|---|
Market Cap | $4.04B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $2.71 |
52-Week Low | $12.30 | $1.11 |
Enterprise Value | $4.10B | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
PLBY Group trades at $1.255, up 6.36% with bullish technical signals from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains thin at 0.23%. Recent developments include inclusion in Russell indexes and strategic share repurchases. Analyst consensus is strongly positive with 75% buy ratings.
The outlook suggests gradual recovery with projected 2026 profitability, though high P/E of 68 and negative shareholder equity pose valuation concerns. Key opportunities include licensing growth and brand expansion, while risks involve debt burden and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
